论文部分内容阅读
目的探讨骨肉瘤组织中雌激素受体（ＥＲ）、孕激素受体（ＰＲ）的表达及其与临床特征的关系。方法应用免疫组化改良ＳＰ方法对６５例骨肉瘤蜡块组织进行了ＥＲ、ＰＲ检测。结合临床特点进行统计学分析。所有病人术前均未接受内分泌治疗。结果骨肉瘤中ＥＲ表达的阳性率为４０％（２６／６５），ＰＲ表达的阳性率为３２３％（２１／６５）；临床无转移，存活时间长之骨肉瘤中ＥＲ、ＰＲ表达的阳性率高于临床有转移、存活时间短者，差异有显著性意义（Ｐ＜００５）；不同性别、年龄、发病部位的骨肉瘤中ＥＲ、ＰＲ表达的阳性率无显著性差异（Ｐ＞００５）。结论骨肉瘤中存在ＥＲ、ＰＲ，ＥＲ、ＰＲ的检测可提示为骨肉瘤生物学行为，对病人预后的评估及探讨骨肉瘤内分泌治疗提供重要的理论依据。
Objective To investigate the expression of estrogen receptor (ER) and progesterone receptor (PR) in osteosarcoma and its relationship with clinical characteristics. Methods ER and PR were detected in 65 cases of osteosarcoma tissue by immunohistochemistry and SP method. Statistical analysis was performed combining clinical features. All patients did not receive endocrine therapy before surgery. Results The positive rate of ER expression in osteosarcoma was 40% (26/65), and the positive rate of PR expression was 32. 3% (21/65). The expression of ER and PR in osteosarcoma with no metastasis and long survival time was found. The positive rate was higher than that of metastasis and short survival time (P<005). There was no significant difference in the positive rate of ER and PR expression among osteosarcomas of different genders, ages, and sites of disease (P). >005). Conclusion The presence of ER, PR, ER, and PR in osteosarcoma may be an indication of the biological behavior of osteosarcoma. It provides an important theoretical basis for evaluating the prognosis of patients and exploring the endocrine treatment of osteosarcoma.